Unknown PHASE2 INTERVENTIONAL 1-arm NCT05193292

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer: A Prospective, Single-arm, Open-label Study

Sponsor: Fudan University

Conditions Colorectal Neoplasms Intestinal Neoplasms

Interventions Camrelizumab FOLFIRI regimen Trastuzumab XELOX regimen mFOLFOX6 regimen mIRIS regimen mXELIRI regimen

Updated 4 times since 2022 Last updated: Jan 2, 2022 Started: Jan 31, 2022 Primary completion: Jan 31, 2024 Completion: Jan 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Colorectal Neoplasms and Intestinal Neoplasms, this trial is ongoing. The trial is conducted by Fudan University and has accumulated 4 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Feb 2025 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Feb 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Feb 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China